The gene-editing therapy, called Casgevy, uses Crispr to prevent debilitating pain in patients with sickle cell disease. It also eliminates the need for regular blood transfusions in people with beta thalassemia.
from Feed: All Latest https://ift.tt/VsjvRy1
via IFTTT
from Feed: All Latest https://ift.tt/VsjvRy1
via IFTTT